HIV JournalView

Table of Contents

• Tenofovir + Emtricitabine + Efavirenz vs. Zidovudine/Lamivudine + Efavirenz
• Adherence, Viral Fitness and NNRTI and PI Resistance
• Clinical Course Following Initiation of HIV Therapy: A Comparison of Developed and Developing Nations
• Disappointing Results With Once-Daily Enfuvirtide
• Enfuvirtide: Once-Daily Dosing Not Possible, but What About Needleless Dosing?
• References

Tenofovir + Emtricitabine + Efavirenz vs. Zidovudine/Lamivudine + Efavirenz

A review of:
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Joel E. Gallant, Edwin DeJesus, José R. Arribas, Anton L. Pozniak, Brian Gazzard, Rafael E. Campo, Biao Lu, Damian McColl, Steven Chuck, Jeffrey Enejosa, John J. Toole, Andrew K. Cheng, for the Study 934 Group. The New England Journal of Medicine. January 19, 2006;354(3):251-260.

The rise of tenofovir (TDF, Viread) for first-line therapy -- and the simultaneous downfall of stavudine (d4T, Zerit) -- was sealed by the results of one study: Gilead 903. Admittedly, by the time the study results were published in the Journal of the American Medical Association in 2004,¹ stavudine had already fallen far from grace; it had been implicated in an increasing number of complications, including neuropathy, pancreatitis, lactic acidosis, fat wasting and elevated lipids. Gilead 903, however, was the nail in stavudine's casket: It demonstrated once and for all stavudine's limitations, while at the same time it presented a convenient and potent alternative: tenofovir. As market share for stavudine plunged, sales of tenofovir rose.

...

Want to read the rest of this article? To learn more about our audience, we're asking readers to register in order to receive full access to all of our materials. Please click here to begin your quick, free registration at The Body PRO.

If you're already registered with The Body PRO, please log in:

E-mail Address
Password
	Remember my login

Forgot your password?